

**Mouse Anti-Human Epididymis Protein 4/HE4/WFDC2 [5B2D9]:MC0345**

**Intended Use:** For Research Use Only

**Description:** The Human Epididymis Protein 4 (HE4), also named WAP four-disulfide core domain protein 2 (WFDC2), is a 25 kDa secreted glycoprotein and is expressed in the epididymis, uterus, and tracheal tissues. HE4 is expressed in a number of normal tissues, and it is also highly expressed in a number of tumors cells lines, such ovarian, colon, breast, lung and renal cells lines. The value of serum HE4 as a biomarker for ovarian and endometrial cancers has been well recognized. Overexpression of HE4 enhanced the malignant behavior of cancer cells including proliferation, invasion, and colony formation. Studies have shown HE4 expression in other malignant tumors including lung adenocarcinoma, stomach cancer and pancreatic cancer.

**Specifications**


Clone: 5B2D9  
 Source: Mouse  
 Isotype: IgG1  
 Reactivity: Human  
 Localization: Cytoplasm, nucleus  
 Formulation: Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)  
 Storage: Store at 2°- 8°C  
 Applications: IHC  
 Package:

Description	Catalog No.	Size
Human Epididymis Protein 4/HE4/WFDC2 Concentrated	MC0345	1 ml

**IHC Procedure\***

Positive Control Tissue: Lung, ovarian carcinoma  
 Concentrated Dilution: 50-200  
 Pretreatment: Tris EDTA pH9.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C  
 Incubation Time and Temp: 30-60 minutes @ RT  
 Detection: Refer to the detection system manual

\* Result should be confirmed by an established diagnostic procedure.



FFPE human ovary cancer stained with anti-HE4 using DAB

**References:**

1. Human epididymis protein 4 may not be a reliable screening biomarker for detecting lung carcinoma patients. Celik B & Bulut T. Biomed Rep 7:297-300, 2017.
2. The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer. Li-e Zheng, et al. Open Med (Wars). 11(1): 125–132, 2016.
3. Immunohistochemical localization of HE4 in benign, borderline, and malignant lesions of the ovary. Georgakopoulos P, et al. Int J Gynecol Pathol. Nov;31(6):517-23, 2012.